Compugen Ltd. (CGEN) Announces Discovery Platform to Predict Cell Penetrating Peptides for Drug Delivery
Israeli drug and diagnostic product discovery company Compugen Ltd. today announced the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. The company also reported that as part of the validation process for the new platform, more than twenty novel peptides demonstrated the predicted cell penetrating properties in initial experimental validation studies. The delivery of biological molecules across selectively permeable cell membranes and into the cells represents a major challenge for the pharmaceutical industry. Important classes of drugs now under development need to enter cells to be effective. Since most are unlikely…